Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
NCT06567717Phase 2Recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Nov 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zinc, nicotinamide riboside in idiopathic pulmonary fibrosis (IPF), sponsored by Cedars-Sinai Medical Center. Started Nov 2025; status: recruiting.
02
Drugs
zincnicotinamide riboside
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06567717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567717.